To read the full story, subscribe or sign in.

Iacta Pharmaceuticals and Zhaoke Ophthalmology agree to co-develop novel eye treatments

Aug. 4, 2020

HONG KONG – California-based Iacta Pharmaceuticals Inc. and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical Ltd. have inked a definitive license agreement for two of Iacta’s products.

BioWorld Asia Deals and M&A Ocular Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for March 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 4, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...

Clots and metastasis in cancer patients start in the lung

BioWorld MedTech

The lung and thrombosis may play a key role in cancer and metastasis progression, according to a collaborative study led by Cornell University scientists. In the...